Boehringer Ingelheim Pharmaceuticals and Eli Lilly announced the FDA has approved a supplemental new drug application for Tradjenta tablets for use as add-on therapy to insulin. Tradjenta is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results